Q-omics provides the consensus-scored TTC39B profile across patient tissues and cancer cell-line models. TTC39B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC39B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TTC39B RNA expression shows 18,863 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TTC39B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC39B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC39B survival associations across molecular data types. TTC39B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC39B RNA expression–survival associations across cancer types. High TTC39B expression shows unfavorable associations in STAD and LGG, but favorable associations in KIRC, LUSC, SKCM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC39B RNA expression.
This table summarizes TTC39B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC39B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC39B shows lower tumor expression in KIRC, LUAD, KIRP and LUSC and higher tumor expression in THCA and BRCA. The THCA box plot shows higher TTC39B RNA expression in tumor versus normal tissue (log2 FC = +0.930, t-test p < 0.001).
This table shows molecular features associated with TTC39B in patient tissues and cancer cell lines. In patient samples, TTC39B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC39B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
